Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716377 · ClinicalTrials.gov registry record · Phase 2
Healing With Venlafaxine After Injury (HELP)
A Phase 2 study, sponsored by Rhode Island Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01716377 is a Phase 2 study that has completed, run by Rhode Island Hospital. The registered enrollment target is 20 participants.
The verdict
NCT01716377, a Phase 2 study, has completed, sponsored by Rhode Island Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Purpose: The purpose of this study is to demonstrate the potential efficacy of venlafaxine administration in reducing acute and chronic musculoskeletal pain in individuals presenting to the ED for evaluation after motor vehicle collision. Participants: Participants will consist of 60 patients between the ages of 18-50 who present to the ED within 12 hours post-motor vehicle collision. Patients who report a neck pain score \> 6 will be screened for further eligibility. Procedures (methods): Using a placebo-controlled, randomized, double-blind trial design, 60 high risk patients will be randomized to venlafaxine vs. placebo in the ED. The ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed during serial short-term telephone follow-ups as well as more in-depth follow-ups at 6 weeks, 4 months, and 6 months post-MVC.
Interventions
- DRUG Venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01716377
The ClinicalTrials.gov registry entry for NCT01716377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Venlafaxine is the first listed.
NCT01716377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01716377 about?
NCT01716377 is a clinical study titled "Healing With Venlafaxine After Injury (HELP)". Purpose: The purpose of this study is to demonstrate the potential efficacy of venlafaxine administration in reducing acute and chronic musculoskeletal pain in individuals presenting to the ED for evaluation after motor vehicle collision. Participants: Participants will consist of 60 patients betwe...
What is the current status of trial NCT01716377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-10. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01716377?
The interventions under investigation include: Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT01716377?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.